Pramod K Mistry (P K Mistry)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Topics

Multiple Myeloma

Replacement Therapy

Hypertrophic Cardiomyopathy

Top Venues

American journal of hematology

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Pramod K Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny L Carwile, Antonio Oliveira-Dos-Santos, Maria Gabriela Perichon, Sefika Uslu Cil, Priya S Kishnani
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. American journal of hematology 99 (8) (2024)
Pramod K Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny L Carwile, Antonio Oliveira-Dos-Santos, Maria Gabriela Perichon, Sefika Uslu Cil, Priya S Kishnani
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. American journal of hematology (2024)
Pramod K Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny L Carwile, Antonio Oliveira-Dos-Santos, Maria Gabriela Perichon, Sefika Uslu Cil, Priya S Kishnani
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. American journal of hematology 99 (8) (2024)
Mohsen Basiri, Mohammad E Ghaffari, Jiapeng Ruan, Vagishwari Murugesan, Nathaniel Kleytman, Glenn Belinsky, Amir Akhavan, Andrew Lischuk, Lilu Guo, Katherine Klinger, Pramod K Mistry
Osteonecrosis in Gaucher Disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center. eLife 12 (2023)
I C Verma, A El-Beshlawy, A Tylki-Szymańska, A Martins, Y-L Duan, T Collin-Histed, M Schoneveld van der Linde, R Mansour, V C Dũng, Pramod K Mistry
Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise. Orphanet journal of rare diseases 17 (1) (2022)
Barry E Rosenbloom, Maria Domenica Cappellini, Neal J Weinreb, Marta Dragosky, Shoshana Revel-Vilk, Julie L Batista, Davorka Sekulic, Pramod K Mistry
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. American journal of hematology 97 (10) (2022)
Pramod K Mistry, P Kishnani, C Wanner, D Dong, J Bender, J L Batista, J Foster
Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. Orphanet journal of rare diseases 17 (1) (2022)
Chandra Sekhar Boddupalli, Shiny Nair, Glenn Belinsky, Joseph Gans, Erin Teeple, Tri-Hung Nguyen, Sameet Mehta, Lilu Guo, Martin L Kramer, Jiapeng Ruan, Honggge Wang, Matthew Davison, Dinesh Kumar, D J Vidyadhara, Bailin Zhang, Katherine Klinger, Pramod K Mistry
Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. eLife 11 (2022)
Pramod K Mistry, Elena A Lukina, Hadhami Ben Turkia, Suma P Shankar, Hagit Baris Feldman, Marwan Ghosn, Atul Mehta, Seymour Packman, Heather Lau, Milan Petakov, Sarit Assouline, Manisha Balwani, Sumita Danda, Evgueniy Hadjiev, Andres Ortega, Meredith C Foster, Sebastiaan J M Gaemers, M Judith Peterschmitt
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. American journal of hematology 96 (9) (2021)
Pramod K Mistry, Manisha Balwani, Joel Charrow, Priya Kishnani, Claus Niederau, Lisa H Underhill, Monica R McClain
Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. American journal of hematology 95 (9) (2020)
Guillermo Drelichman, Gilberto Castañeda-Hernández, Muhlis Cem Ar, Marta Dragosky, Ricardo Garcia, Howard Lee, Sergey V Moiseev, Majid Naderi, Hanna Rosenbaum, Irena Žnidar, Andrés Felipe Zuluaga, Selena Freisens, Pramod K Mistry
The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease. American journal of hematology 95 (3) (2019)
Neal J Weinreb, Pramod K Mistry, Barry E Rosenbloom, Madhav V Dhodapkar
MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood 131 (22) (2018)
Pramod K Mistry, Elena Lukina, Hadhami Ben Turkia, Suma P Shankar, Hagit Baris, Marwan Ghosn, Atul Mehta, Seymour Packman, Gregory Pastores, Milan Petakov, Sarit Assouline, Manisha Balwani, Sumita Danda, Evgueniy Hadjiev, Andres Ortega, Sebastiaan J M Gaemers, Regina Tayag, M Judith Peterschmitt
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. American journal of hematology 92 (11) (2017)
Pramod K Mistry, Julie L Batista, Hans C Andersson, Manisha Balwani, Thomas Andrew Burrow, Joel Charrow, Paige Kaplan, Aneal Khan, Priya S Kishnani, Edwin H Kolodny, Barry Rosenbloom, C Ronald Scott, Neal J Weinreb
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. American journal of hematology 92 (9) (2017)